Founded in March 2015, EUSA Pharma is a profitable commercial-stage specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. EUSA Pharma has a portfolio of approved Oncology therapeutic and supportive care products including: FOTIVDA® (tivozanib) for the treatment of advanced RCC, QARZIBA® (dinutuximab beta) for the treatment of HR Neuroblastoma, Caphosol® and Caphosol® DISPERSIBLE, for the treatment and prevention of Oral Mucositis.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.